स्वास्थ्य
DCGI Grants Approval for Advanced Immunotherapy Drug Zytorvi for Esophageal Cancer Treatment
The Drugs Controller General of India has officially approved the use of Zytorvi (Toripalimab), a modern immunotherapy drug, for the treatment of esophageal cancer.
The Drugs Controller General of India (DCGI) has issued a green signal for the use of a new advanced immunotherapy drug in the treatment of esophageal cancer. The regulatory body has granted official approval for the use of Zytorvi, which is the brand name for the drug Toripalimab.
This approval marks a significant development in cancer care in India, providing patients with access to a modern and advanced therapeutic option. Zytorvi is classified as an immunotherapy agent, a treatment modality that works by helping the body’s immune system recognize and attack cancer cells.
The decision by the Indian drug regulatory authority ensures that this specific medication can be legally prescribed and distributed for the management of esophageal cancer. The approval highlights the ongoing efforts to bring global advancements in oncology treatments to the Indian healthcare system.
This approval marks a significant development in cancer care in India, providing patients with access to a modern and advanced therapeutic option. Zytorvi is classified as an immunotherapy agent, a treatment modality that works by helping the body’s immune system recognize and attack cancer cells.
The decision by the Indian drug regulatory authority ensures that this specific medication can be legally prescribed and distributed for the management of esophageal cancer. The approval highlights the ongoing efforts to bring global advancements in oncology treatments to the Indian healthcare system.